1. Home
  2. FORTY vs NVCR Comparison

FORTY vs NVCR Comparison

Compare FORTY & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Formula Systems (1985) Ltd.

FORTY

Formula Systems (1985) Ltd.

HOLD

Current Price

$114.00

Market Cap

2.0B

Sector

Technology

ML Signal

HOLD

Logo NovoCure Limited

NVCR

NovoCure Limited

HOLD

Current Price

$16.44

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FORTY
NVCR
Founded
1985
2000
Country
Israel
Switzerland
Employees
N/A
N/A
Industry
EDP Services
Medical/Dental Instruments
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
2.0B
IPO Year
1998
2015

Fundamental Metrics

Financial Performance
Metric
FORTY
NVCR
Price
$114.00
$16.44
Analyst Decision
Buy
Analyst Count
0
6
Target Price
N/A
$28.08
AVG Volume (30 Days)
403.0
934.5K
Earning Date
05-21-2026
04-30-2026
Dividend Yield
1.32%
N/A
EPS Growth
N/A
21.79
EPS
N/A
N/A
Revenue
N/A
$655,353,000.00
Revenue This Year
N/A
$7.72
Revenue Next Year
N/A
$6.74
P/E Ratio
$36.65
N/A
Revenue Growth
N/A
8.28
52 Week Low
$102.01
$9.82
52 Week High
$190.56
$21.45

Technical Indicators

Market Signals
Indicator
FORTY
NVCR
Relative Strength Index (RSI) 47.09 47.26
Support Level $109.49 $16.33
Resistance Level $119.68 $18.43
Average True Range (ATR) 1.46 0.67
MACD 0.54 -0.02
Stochastic Oscillator 37.86 45.84

Price Performance

Historical Comparison
FORTY
NVCR

About FORTY Formula Systems (1985) Ltd.

Formula Systems (1985) Ltd is an information technology company that is principally engaged through its directly and indirectly held investees in providing software consulting services, selling and marketing computer-based business solutions and hardware products from a wide range of domestic and international manufacturers, as well as developing proprietary software solutions. It delivers solutions in Israel and in numerous countries to customers with complex IT services needs. It designs and implements IT solutions and software systems that improve the productivity of customers' existing IT assets, enable them to effectively manage their operations and reduce their business risks in the face of changing business environments.

About NVCR NovoCure Limited

NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.

Share on Social Networks: